|
|
|
|
| 01.04.09 |
|
Dr. Rajkumar - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA
|
|
|
Dr. Vincent Rajkumar
Mayo Clinic
Rochester, Minnesota
USA
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
 |
|
|
| 01.04.09 |
|
Dr. Anderson - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
U.S.A.
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Gertz - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008 in San Francisco, CA and
|
|
|
Morie Gertz, MD
Mayo Clinic
Rochester, Minnesota
USA
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
UPDATE ON BANK ON A CURE RESEARCH:
|
|
|
| 01.04.09 |
|
Dr. Van Ness - ASH 2008 - Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma
|
|
|
Brian Van Ness, PhD
University of Minnesota
Institute of Human Genetics
Minneapolis, Minnesota
USA
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
|
| 01.04.09 |
|
Dr. Reece - ASH 2008 - The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
|
|
|
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Ontario
Canada
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Munshi - ASH 2008 - Alternate Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A High-Density Exon Array Analysis of Uniformly Treated Newly-Diagnosed Myeloma Patients
|
|
|
Nikhil Munshi, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
USA
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Morgan - ASH 2008 - Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients
|
|
|
Gareth Morgan, MD
Section of Haemato-Oncology
The Institute of Cancer Research
London, United Kingdom
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Morgan - ASH 2008 - High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma
|
|
|
Gareth Morgan, MD
Section of Haemato-Oncology
The Institute of Cancer Research
London, United Kingdom
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Goldschmidt - ASH 2008 - Inhibition of Aurora-Kinases for Tailored Risk-Adapted Treatment of Multiple Myeloma
|
|
|
Hartmut Goldschmidt, MD
Universitätsklinikum Heidelberg und Nationales Centrum für Tumorerkrankungen
Heidelberg, Germany
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Beksac - ASH 2008 - HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM)
|
|
|
Meral Beksac, MD
Ankara University School of Medicine
Ankara, Turkey
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
NEWLY-DIAGNOSED: TRANSPLANT ELIGIBLE:
|
|
|
| 01.04.09 |
|
Dr. San Miguel - Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Knop - ASH 2008 - Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial
|
|
|
Stephan Knop, MD
University Hospital Würzburg
Würzburg, Germany
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Sonneveld - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
|
|
|
Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Rotterdam, Netherlands
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Bensinger - ASH 2008 - A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.
|
|
|
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington
U.S.A.
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Lokhorst - ASH 2008 - Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)
|
|
|
Henk M. Lokhorst, MD
University Medical Center Utrecht
Utrecht, Netherlands
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Kumar - Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Kumar - ASH 2008 - Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota
U.S.A.
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Kumar - ASH 2008 - Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota
U.S.A.
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Palumbo - ASH 2008 - Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results
|
|
|
Antonio Palumbo, MD
Divisione di Ematologia dell'Università di Torino
A.O.U. San Giovanni Battista
Torino, Italy
Member,IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
NEWLY-DIAGNOSED: ELDERLY OR NON-TRANSPLANT:
|
|
|
| 01.04.09 |
|
Dr. Palumbo - ASH 2008 - A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
|
|
|
Antonio Palumbo, MD
Divisione di Ematologia dell'Università di Torino
A.O.U. San Giovanni Battista
Torino, Italy
Member,IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Palumbo - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients
|
|
|
Antonio Palumbo, MD
Divisione di Ematologia dell'Università di Torino
A.O.U. San Giovanni Battista
Torino, Italy
Member,IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Wijermans - ASH 2008 - Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study
|
|
|
Pierre Wijermans, MD
Haga Hospital
The Hague, Netherlands
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Hajek - ASH 2008 - The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance
|
|
|
Roman Hajek, MD
University Hospital Brno
Brno, Czech Republic
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Harousseau - ASH 2008 - Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone
|
|
|
Jean-Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
|
| 01.04.09 |
|
Dr. Jakubowiak - ASH 2008 - Initial Treatment with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, Michigan
U.S.A.
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Lonial - ASH 2008 - A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia
U.S.A.
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Barlogie - ASH 2008 - Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5
|
|
|
Bart Barlogie, MD, PhD
University of Arkansas for Medical Sciences
Myeloma Institute for Research and Therapy
Little Rock, Arkansas
USA
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Avigan - Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma
|
|
|
David Avigan, MD
Beth Israel Deaconess Medical Center
Boston Massachusetts
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Bladé - ASH 2008 - Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial
|
|
|
Joan Bladé, MD
Hospital Clinic
Barcelona, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Niederwieser - ASH 2008 - Overview of the European Bone Marrow Transplant Group (EBMT)
|
|
|
Dietger W. Niederwieser, MD
University of Leipzig
Leipzig, Germany
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Harousseau - ASH 2008 - Velcade-Dexamethasone versus VAD as Induction Treatment Prior to ASCT in Newly Diagnosed MM. Updated Results of the IFM2005/01 Trial.
|
|
|
Jean-Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Cavo - ASH 2008 - Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma; Up-Front Response Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities
|
|
|
Michele Cavo, MD
Bologna University School of Medicine
Seragnoli Institute of Hematology and Medical Oncology
Bologna, Italy
|
|
|
|
| |
|
|
|
|
|
|
|
| 01.04.09 |
|
Dr. Rajkumar - ASH 2008 - Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome
|
|
|
Dr. Vincent Rajkumar
Mayo Clinic
Rochester, Minnesota
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Dispenzieri - ASH 2008 - Primary Therapy with Bortezomib—the Role of Induction, Maintenance, and Re-Induction in Patients with High Risk Myeloma. Update of Results from E2A02
|
|
|
Angela Dispenzieri, MD
Mayo Clinic
Rochester, Minnesota
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Landau - ASH 2008 - Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response
|
|
|
Heather Landau, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
U.S.A.
|
|
|
|
| |
|
|
|
|
|
|
RELAPSED-REFRACTORY DISEASE:
|
|
|
| 01.04.09 |
|
Dr. Reece - ASH 2008 - Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
|
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Ontario
Canada
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Petrucci - ASH 2008 - Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial
|
|
|
Maria Teresa Petrucci, MD
Università La Sapienza
Rome, Italy
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Reece - ASH 2008 - Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion
|
|
|
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Ontario
Canada
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Weber - ASH 2008 - Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience
|
|
|
Donna Weber, MD
M.D. Anderson Cancer Center
Houston Texas
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Morgan - ASH 2008 - CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
|
|
|
Gareth Morgan, MD
Section of Haemato-Oncology
The Institute of Cancer Research
London, United Kingdom
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
|
| 01.04.09 |
|
Dr. Jakubowiak - ASH 2008 - Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, Michigan
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Kaufman - ASH 2008 - First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma
|
|
|
Jonathan Kaufman, MD
Emory University School of Medicine
Winship Cancer Institute
Atlanta Georgia
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. San Miguel - ASH 2008 - Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Knop - ASH 2008 - Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial
|
|
|
Stephan Knop, MD
University Hospital Würzburg
Würzburg, Germany
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Lonial - ASH 2008 - A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Miki - ASH 2008 - KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts
|
|
|
Hirokazu Miki, MD
Tokushima Uiveristy HospitalTokushima, Japan
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Vogl - ASH 2008 - Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma
|
|
|
Dan T. Vogl, MD
Abramson Cancer Center, University of Pennsylvania School of Medicine
Myeloma Program
Philadelphia, Pennsylvania
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Vij - ASH 2008 - Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)
|
|
|
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri
USA
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Lacy - ASH 2008 - Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma
|
|
|
Martha Q. Lacy, MD
Mayo Clinic
Rochester, Minnesota
U.S.A.
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Zonder - ASH 2008 - Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma
|
|
|
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Pozzi - ASH 2008 - Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease
|
|
|
Samantha Pozzi, MD
Dana-Farber Cancer Institute
Jerome Lipper Multiple Myeloma Disease CenterBoston Massachusetts
USA
2009 IMF Grant Recipient
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Jagannath - ASH 2008 - Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York
USA
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
| 01.04.09 |
|
Dr. Santo - ASH 2008 - AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β
|
|
|
Loredana Santo, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
USA
2009 IMF Grant Recipient
|
|
|
|
| |
|
|
|
|
|
|
|
| 01.04.09 |
|
Dr. Ludwig - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
|
|
|
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
|
| 01.04.09 |
|
Dr. Morgan - ASH 2008 - Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation
|
|
|
Gareth Morgan, MD
Section of Haemato-Oncology
The Institute of Cancer Research
London, United Kingdom
Member, IMF Board of Scientific Advisors
|
|
|
|
| |
|
|
|
|
|
|
|
| 01.20.09 |
|
Multiple Myeloma: Finding Your Way Through the Treatment Maze - Selecting the Best Treatment in the Era of Novel Agents
|
|
|
Audiocast of the IMF Super Friday Program at the 50th ASH Annual Meeting and Exposition
|
|
|
|
| |
|
|
|
|
